Radiolabeled lymphatic staining agents and methods for making

Abstract

A radiolabeled lymphatic staining agent is mixed on site with a much larger amount, on a weight basis, of a non-radiolabeled lymphatic staining agent to form an injectable radiolabeled lymphatic staining agent suitable for surgical use in humans. Preferably, the radiolabel is I-125, because it has a 60-day half-life which enables it to be made off-site. The preferred radiolabeled lymphatic staining agent is iodinated methylene blue, because it can be mixed with a range of non-radioactive lymphatic staining agents, for example isosulfan blue, methylene blue, patent blue, and patent blue V, to provide the injected agent with sufficient radioactivity to enable machine detection. A method for making radioiodinated methylene blue is also disclosed.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application is a division of copending application Ser. No. 10 / 884,561, filed Jul. 2, 2004, now ______.SPECIFICATION[0002]1. Field of the Invention[0003]In one aspect, the invention relates to radiolabeled lymphatic staining agents which are useful for detection of the sentinel lymph node draining a tumor site. In another aspect, the invention relates to a method for making such a staining agent. In a further aspect, the invention relates to a method for providing radiolabeled staining agents for use in lymph node detection.[0004]2. Background of the Invention[0005]One of the major techniques for determining the prognosis of cancer, particularly breast cancer, involves examining the lymph nodes of the axilla or armpit of the patient. It is well known that a major aspect in assessing the stage of the cancer revolves around whether the cancer has spread to the lymph nodes. It is therefore important to have an effective technique for ide...

AI Technical Summary

Benefits of technology

[0019]The method provides a more economical procedure for supplying radiolabeled lymphatic staining agent than current practice, in which the radioactive agent is made on site daily, or the entirety of the injectable staining agent is radiolabeled. In the preferred embodiment, the radioisotope selected has a half-life in the range of 2 days to 2 years, to avoid excessive loss of radioactivity during the shipment process.

Problems solved by technology

With the development of sentinel node biopsy came some unanticipated consequences for both surgeon and patient alike.

The injection of radiocolloid is unusually painful whether it is injected in small quantities intradermally or in larger quantities around the tumor.

Failure to allow clearance of the radiolabeled colloid “swamps” the gamma detector making identification of the sentinel node impossible or at least much more difficult.